Drugs / SGN-CD123A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02848248 | Aug 2016 → Apr 2018 | acute myeloid leukemia | Seagen Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN-CD123A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02848248 ↗ |
| Action | Deplete | “In vitro, SGN-CD123A-mediated potent cytotoxicity of 11/12 CD123+ AML cell lines and 20/23 primary samples from AML patients” PMID 29142066 ↗ Nov 2017 |
| Route | Intravenous | “Intravenous infusion in 3-week cycles” NCT02848248 ↗ |